Close Menu

BioSystem Development

By Adam Bonislawski
Agilent Technologies and Integrated Diagnostics said this week that they have entered a strategic partnership to develop mass spec workflows for protein biomarker diagnostics.

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of BioSystem Development for an undisclosed sum.

NEW YORK (GenomeWeb News) – Agilent Technologies today announced two deals that are expected to grow its footprint in the life science space.

The firm, which makes the AssayMap platform, plans to use the funds to scale up its manufacturing capabilities, increase the speed to market of its new products, and support expansion of its product pipeline.

Agilent will integrate mass-tagged PCR primers with LC-MS to enable the rapid identification of food-borne pathogens in one deal with UC-Davis, and combine its automated liquid handling platform with BioSystem's AssayMap high-throughput micro-chromatography technology in another collaboration.

The firms are combining their respective technologies to provide a platform that they said could process hundreds of samples in three hours or less.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.